|6.90|| -0.10 / -1.43%|
Agenus, Inc. is a biotechnology company, which is focused on the development and commercialization of technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its core technology portfolio consists of Saponin platform and Heat Shock Protein platform. The company within its Saponin Platform is QS-21 Stimulon adjuvant, or QS-21 Stimulon, which is used by its licensees in numerous vaccines under development in clinical trials, some as advanced as phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer's disease, human immunodeficiency virus and tuberculosis. Agenus within its HSP Platform is developing its recombinant series and prophage series vaccines. The company's HerpV, a therapeutic vaccine candidate from the recombinant series, which contains QS-21 Stimulon, has been tested in a phase 1 clinical trial for the treatment of genital herpes. Agenus was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
|Garo H. Armen||Chairman & Chief Executive Officer|
|Christine M. Klaskin||Chief Financial & Accounting Officer|
|Robert B. Stein||President-Research & Development|
|Alexander R. Duncan||Chief Technology Officer|
|Karen Higgins Valentine||Secretary, Chief Compliance Officer & VP|